Malignant neoplasm of cardio-esophageal junction of stomach clinical trials in Illinois
3 active Malignant neoplasm of cardio-esophageal junction of stomach trials with a site in Illinois. Describe your situation to see which ones look like a fit.
- Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase 1/1b Study of IAM1363 in HER2 Cancers
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
← All Malignant neoplasm of cardio-esophageal junction of stomach trials